ALSO READGranules India intimates of successful USFDA inspection of Gagillapur facility Granules India Q1 net up 37 pc at Rs 39 cr Granules acquires rights for 4 products from USpharma Windlas Granules India inches up after USFDA nod for Ibuprofen tablets Granules India gains after its plant receives inspection report from USFDA
Pharma firm Granules India today said its Gagillapur facility in Hyderabad has completed USFDA inspection without any observations. "The company's Gagillapur facility located in Hyderabad, Telangana...
Has successfully completed US FDA inspection without any observations," Granules India said in a BSE filing. "This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs)." The stock of Granules India was trading 2.29 per cent higher at Rs 122.75 on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)